Hemophilia Therapy Innovation: Development of an Advanced Category Recombinant Factor VIII by a Plasma/Albumin-Free Method: Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK

Seminars in Hematology

Volumn 41, Issue 1 SUPPL. 2, 2004, Pages 1-16

  Ewenstein, Bruce M ^a   Collins, P ^b   Tarantino, M D ^b   Negrier, C ^b   Blanchette, V ^b   Shapiro, A D ^b   Baker, D ^b   Spotts, G ^b   Sensel, M ^b   Yi, S E ^b   Gomperts, E D ^b  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MANNITOL; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT DNA; SERUM ALBUMIN; SUCROSE; TREHALOSE;

BLOOD SUBSTITUTION; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; EVALUATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SUBSTITUTION THERAPY; TREATMENT OUTCOME;

EID: 11144354028     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2003.11.001     Document Type: Conference Paper

References (53)

1. Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusions. JAMA 289:959-962, 2003
2. Hilgartner MW: The need for recombinant factor VIII: Historical background and rationale. Semin Hematol 28:6-9, 1991
3. Jones PK, Ratnoff OD: The changing prognosis of classic hemophilia (factor VIII "deficiency"). Ann Intern Med 114: 641-648, 1991
4. Schimpf K: On the way to virus-safe blood coagulation factor concentrates. Semin Thromb Hemost 28:15-24, 2002 (suppl 1)
5. Abshire TC, Brackmann HH, Scharrer I, et al: Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 83:811-816, 2000
6. Aygoren-Pursun E, Scharrer I: German Kogenate Study Group: A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 78:1352-1356, 1997
7. Bray GL, Gomperts ED, Courter S, et al: A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 83:2428-2435, 1994
8. Courter SG, Bedrosian CL: Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 38:44-51, 2001
9. Hoots WK: History of plasma-product safety. Transfus Med Rev 15:3-10, 2001
10. Lusher JM, Lee CA, Kessler CM, et al: The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 9:38-49, 2003
11. Rothschild C, Scharrer I, Brackmann HH, et al: European data of a clinical trial with a sucrose formulated recombinant factor VIII in previously treated haemophilia A patients. Haemophilia 8:10-14(suppl 2, abstr), 2002
12. Schwartz RS, Abildgaard CF, Aledort LM, et al: Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med 323:1800-1805, 1990
13. Schlesinger KW, Ragni MV: Safety of the new generation recombinant factor concentrates. Expert Opin Drug Saf 1:213-223, 2002
14. Suiter TM: First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely? Semin Thromb Hemost 28:277-284, 2002
15. Lusher JM: First and second generation recombinant factor VIII concentrates in previously untreated patients: Recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost 28:273-276, 2002
16. Schonberger LB: New variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Infect Dis Clin North Am 12:111-121, 1998
17. Ricketts MN: Is Creutzfeldt-Jakob disease transmitted in blood? Is the absence of evidence of risk evidence of the absence of risk? Can Med Assoc J 157:1367-1370, 1997
18. Gruppo R, Bray GL, Schroth P, et al: Safety and immunogenicity of recombinant factor VIII (Recombinate™) in previously untreated patients (PUPs): A 6.5 year update. Thromb Haemost 162, 1997 (suppl, abstr)
19. White GC, Courter S, Bray GL, et al: A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 77:660-667, 1997
20. Toole JJ, Knopf JL, Wozney JM, et al: Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312: 342-347, 1984
21. Wood WI, Capon DJ, Simonsen CC, et al: Expression of active human factor VIII from recombinant DNA clones. Nature 312:330-337, 1984
22. Gitschier J, Wood WI, Goralka TM, et al: Characterization of the human factor VIII gene. Nature 312:326-330, 1984
23. Kaufman RJ, Pipe SW, Tagliavacca L, et al: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 8:S3-14, 1997 (suppl 2)
24. Lenting PJ, van Mourik JA, Mertens K: The life cycle of coagulation factor VIII in view of its structure and function. Blood 92:3983-3996, 1998
25. Pipe SW, Morris JA, Shah J, et al: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 273:8537-8544, 1998
26. Moussalli M, Pipe SW, Hauri HP, et al: Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII. J Biol Chem 274:32539-32542, 1999
27. Nichols WC, Seligsohn U, Zivelin A, et al: Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 93:61-70, 1998
28. Saenko EL, Scandella D: The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem 272: 18007-18014, 1997
29. Lollar P: The association of factor VIII with von Willebrand factor. Mayo Clin Proc 66:524-534, 1991
30. Pipe SW, Kaufman RJ: Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 94:11851-11856, 1997
31. Gomperts E, Lundblad R, Adamson R: The manufacturing process of recombinant factor VIII, recombinate. Transfus Med Rev 6:247-251, 1992
32. Astermark J: Treatment of the bleeding inhibitor patient. Semin Thromb Hemost 29:77-86, 2003
33. Gruppo RA, Brown D, Wilkes MM, et al: Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - A meta-analysis. Haemophilia 9:251-260, 2003
34. Kaufman RJ, Wasley LC, Davies MV, et al: Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 9:1233-1242, 1989
35. Davis JM, Arakawa T, Strickland TW, et al: Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26:2633-2638, 1987
36. Sasaki H, Bothner B, Dell A, et al: Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 262:12059-12076, 1987
37. Spellman MW, Basa LJ, Leonard CK, et al: Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells. J Biol Chem 264:14100-14111, 1989
38. Mory Y, Ben Barak J, Segev D, et al: Efficient constitutive production of human IFN-gamma in Chinese hamster ovary cells. DNA 5:181-193, 1986
39. Miloux B, Lupker JH: Rapid isolation of highly productive recombinant Chinese hamster ovary cell lines. Gene 149:341-344, 1994
40. Chu L, Robinson DK: Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 12:180-187, 2001
41. Bi L, Lawler AM, Antonarakis SE, et al: Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10:119-121, 1995
42. Martinowitz U, Schulman S: Continuous infusion of coagulation products. Int J Pediatr Hematol Oncol 1:471-478, 1994
43. Martinowitz U, Schulman S, Gitel S, et al: Adjusted dose continuous infusion of factor viii in patients with haemophilia a. Br J Haematol 82:729-734, 1992
44. Schulman S: Continuous infusion. Haemophilia 9:368-375, 2003
45. Batorova A, Martinowitz U: Continuous infusion of coagulation factors. Haemophilia 8:170-177, 2002
46. Seremetis S, Lusher JM, Abildgaard CF, et al: Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: Conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia 5:9-16, 1999
47. Brown P: Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. BMJ 322:841-844, 2001
48. Hunter N, Foster J, Chong A, et al: Transmission of prion diseases by blood transfusion. J Gen Virol 83:2897-2905, 2002
49. Burthem J, Roberts DJ: The pathophysiology of variant Creutzfeldt-Jacob disease: The hypotheses behind concerns for blood components and products. Br J Haematol 122:3-9, 2003
50. Ironside JW, Head MW: Variant Creutzfeldt-Jakob disease and its transmission by blood. J Thromb Haemost 1:1479-1486, 2003
51. United Kingdom Haemophilia Centre Doctor's Organisation: Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9:1-23, 2003
52. Medical and Scientific Advisory Council (MASAC): Recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document #141, March 2003
53. Saenko EL, Ananyeva NM, Shima M, et al: The future of recombinant coagulation factors. J Thromb Haemost 1:922-930, 2003